Literature DB >> 33579394

Prevalence and incidence rate of tuberculosis among HIV-infected patients enrolled in HIV care, treatment, and support program in mainland Tanzania.

M Majigo1, G Somi2, A Joachim3, J Manyahi3, J Nondi2, V Sambu2, A Rwebembera2, N Makyao2, A Ramadhani2, W Maokola2, J Todd4, M I Matee3.   

Abstract

BACKGROUND: Despite improvements in access to antiretroviral therapy (ART), mortality in people living with human immunodeficiency virus (PLHIV) is still high and primarily attributed to tuberculosis (TB) infection. In Sub-Saharan Africa, approximately 80% of HIV-related mortality cases are associated with TB. Relatively little is known about the incidence of TB among PLHIV in Tanzania and the determinant factors. We report the prevalence and incidence rate of confirmed TB and determine association with selected demographic and program-related factors based on data in the national HIV care and treatment program from 2011 to 2014.
METHODS: We used the Tanzania National AIDS Control Programme database to obtain information on all HIV clients enrolled in the HIV care and treatment program between January 2011 and December 2014. We analyzed retrospective cohort data to assess the prevalence and TB incidence rate per 1000 person-years. A multivariable Cox proportional hazards regression model was used to estimate hazard ratios and 95% confidence intervals for putatively associated factors.
RESULTS: Over 4 years, there were 22,071 confirmed cases of pulmonary TB in 1,323,600 person-years. The overall TB incidence was around 16.7 (95% CI 16.4-16.9) cases per 1000 person-years. The annual incidence rate decreased by 12.4 % from 17.0 (95% CI 16.5-17.4) in 2011 to 14.9 (95% CI 14.5-15.4) in 2014. The TB incidence rate was higher in persons not using ART and in males than in females. The incidence of TB was higher in patients with advanced HIV disease and decreased with increasing age. The overall prevalence of TB was 2.2%, with a peak prevalence of 2.5% in 2013 and was higher among children < 15 years (3.2%) in the same year.
CONCLUSION: The study found an overall decrease in the incidence of TB in PLHIV. Our results emphasize the need for early initiation of ART and the provision of TB preventive therapy for those PLHIV without active TB after intensified TB case-finding.

Entities:  

Keywords:  Antiretroviral therapy; Collaborative TB/HIV; HIV; Incidence of tuberculosis; Tuberculosis

Year:  2020        PMID: 33579394      PMCID: PMC7818072          DOI: 10.1186/s41182-020-00264-1

Source DB:  PubMed          Journal:  Trop Med Health        ISSN: 1348-8945


  31 in total

1.  Recommendations of the Interim Policy on Collaborative TB/HIV activities.

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  2004-01-09

2.  Tuberculosis risk factors and mortality for HIV-infected persons receiving antiretroviral therapy in South Africa.

Authors:  Stephanus Komati; Pamela A Shaw; Nomso Stubbs; Monkwe J Mathibedi; Lizette Malan; Phumelele Sangweni; Julia A Metcalf; Henry Masur; Shaheen Hassim
Journal:  AIDS       Date:  2010-07-31       Impact factor: 4.177

3.  Tuberculosis among HIV-infected patients receiving HAART: long term incidence and risk factors in a South African cohort.

Authors:  Stephen D Lawn; Motasim Badri; Robin Wood
Journal:  AIDS       Date:  2005-12-02       Impact factor: 4.177

4.  Incidence of tuberculosis after HAART initiation in a cohort of HIV-positive patients in Burkina Faso.

Authors:  M Dembélé; N Saleri; A C C Carvalho; T Saouadogo; A D Hien; I Zabsonre; S T Koala; J Simporé; A Matteelli
Journal:  Int J Tuberc Lung Dis       Date:  2010-03       Impact factor: 2.373

5.  Factors related to HIV/tuberculosis coinfection in a Brazilian reference hospital.

Authors:  Bráulio Matias de Carvalho; André Jalles Monteiro; Roberto da Justa Pires Neto; Thalles Barbosa Grangeiro; Cristiane Cunha Frota
Journal:  Braz J Infect Dis       Date:  2008-08       Impact factor: 1.949

6.  Tuberculosis risk varies with the duration of HIV infection: a prospective study of European drug users with known date of HIV seroconversion.

Authors:  Liselotte van Asten; Miranda Langendam; Robert Zangerle; Ildefonso Hernández Aguado; Faroudy Boufassa; Veronique Schiffer; Raymond P Brettle; J Roy Robertson; Arnaud Fontanet; Roel A Coutinho; Maria Prins
Journal:  AIDS       Date:  2003-05-23       Impact factor: 4.177

7.  Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study.

Authors:  Motasim Badri; Douglas Wilson; Robin Wood
Journal:  Lancet       Date:  2002-06-15       Impact factor: 79.321

8.  Trends in HIV/TB coinfection in Trinidad and Tobago for the period 1998-2007.

Authors:  Kameel Mungrue; Andrew Beharry; Jason Kalloo; Sunita Mahabir; Tishan Maraj; Ryan Ramoutar; K Ramsaroop; Viren Solomon
Journal:  J Int Assoc Physicians AIDS Care (Chic)       Date:  2009-02-25

Review 9.  Incidence of HIV-associated tuberculosis among individuals taking combination antiretroviral therapy: a systematic review and meta-analysis.

Authors:  Tendesayi Kufa; Tonderai Mabuto; Evans Muchiri; Salome Charalambous; Dominique Rosillon; Gavin Churchyard; Rebecca C Harris
Journal:  PLoS One       Date:  2014-11-13       Impact factor: 3.240

Review 10.  Isoniazid Prophylactic Therapy for the Prevention of Tuberculosis in HIV Infected Adults: A Systematic Review and Meta-Analysis of Randomized Trials.

Authors:  Henok Tadesse Ayele; Maaike S M van Mourik; Thomas P A Debray; Marc J M Bonten
Journal:  PLoS One       Date:  2015-11-09       Impact factor: 3.240

View more
  2 in total

1.  Prevalence of and Factors Associated with Reoccurrence of Opportunistic Infections Among Adult HIV/AIDS Patients Attending the ART Clinic at Public Health Facilities in Arba Minch Town, Southern Ethiopia.

Authors:  Maycas Dembelu; Teklu Woseneleh
Journal:  HIV AIDS (Auckl)       Date:  2021-09-04

2.  Incidence and factors associated with active tuberculosis among people living with HIV after long-term antiretroviral therapy in Thailand: a competing risk model.

Authors:  Sivaporn Gatechompol; Jiratchaya Sophonphan; Sasiwimol Ubolyam; Anchalee Avihingsanon; Frank van Leth; Frank Cobelens; Stephen J Kerr
Journal:  BMC Infect Dis       Date:  2022-04-07       Impact factor: 3.090

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.